Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related death worldwide, with limited durable treatment options despite advances in targeted therapies and checkpoint inhibitors. This program develops a trispecific antibody construct designed to simultaneously bind tumor antigens and activate NK cells, driving a more potent immune response against tumor cells. By integrating NK cell engagement, the approach addresses resistance mechanisms that often limit the efficacy of conventional immunotherapies. Currently in IND-enabling development, the program benefits from a defined CMC roadmap and robust bioanalytical strategy. First-in-human studies are targeted for 2027, with potential to set a new benchmark for NK cell-based immunotherapy in solid tumors.

Glioblastoma is among the most aggressive and treatment-resistant cancers, with median survival measured in months and few meaningful therapeutic options. This program leverages a nanobody therapeutic directed against a key immunosuppressive receptor to counteract tumor-driven immune evasion and re-activate anti-tumor immune function. Nanobodies offer significant advantages in tumor penetration and molecular stability, allowing access to hard-to-reach tumor compartments within the central nervous system. The program is currently advancing through preclinical collaboration with academic and industry partners, generating proof-of-concept data to support further development. If successful, this therapy could introduce a highly differentiated modality to a field with an urgent unmet medical need.

Alzheimer’s disease continues to impose a profound health and economic burden, with existing therapies offering only modest symptomatic relief. This program introduces a dual-target immunotherapy that simultaneously addresses amyloid-beta and tau, the two hallmark drivers of disease pathology. By tackling both proteinopathies in parallel, the approach aims to deliver stronger disease-modifying effects than single-target therapies currently in clinical practice. The program has completed IND-enabling studies and is Phase 1 ready, supported by a robust preclinical data package. With clinical development set to begin, the candidate is well-positioned to become a differentiated therapy in a high-unmet-need neurodegenerative disease space.

We hold an equity stake in a regional CRO leader positioned to scale internationally, enabling high-quality preclinical through Phase II clinical development. The platform investment provides direct access to operational infrastructure, trial networks, and regulatory expertise, accelerating execution across our therapeutic pipeline. With added capacity in the US and Latin America, the CRO enhances global reach while supporting cost-efficient, regionally tailored studies. This strategic position also facilitates integration of novel technologies, such as decentralized trial models and real-world evidence generation. Over the long term, the CRO investment serves as both a financial asset and a cornerstone partner in driving portfolio execution.

Our diagnostics platform develops immune biomarker tools that support precision patient selection and early disease detection. Current initiatives include an SAA-led prodromal Parkinson’s workflow, next-generation TCR/BCR sequencing technologies, and integrated digital endpoints for longitudinal monitoring. These innovations address a growing demand for biomarker-driven clinical trials, where patient stratification and response tracking are critical for success. The platform also serves as a cross-program enabler, creating synergies across oncology, neurology, and immunology pipelines. By embedding biomarker and digital diagnostic capabilities into our R&D ecosystem, we aim to reduce trial risk, accelerate timelines, and improve overall clinical outcomes.